Picture of Regeneron Pharmaceuticals logo

REGN — Regeneron Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Brief: Livsayis™ (Cemdisiran) Approved By The FDA As First And Only Sirna Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing

BRIEF-Livsayis™ (Cemdisiran) Approved By The FDA As First And Only Sirna Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing

- Regeneron Pharmaceuticals, Inc. REGN.O:

  • LIVSAYIS™ (CEMDISIRAN) APPROVED BY THE FDA AS FIRST AND ONLY SIRNA THERAPY IN GENERALIZED MYASTHENIA GRAVIS AND ONLY TREATMENT WITH FOUR-TIMES-A-YEAR SUBCUTANEOUS DOSING

  • REGENERON PHARMACEUTICALS - LIVSAYIS AVAILABLE ONLY THROUGH LIVSAYIS REMS PROGRAM

Source text: ID:nGNX8NFpFK

Further company coverage: REGN.O


((Reuters.Briefs@thomsonreuters.com;;))

Recent news on Regeneron Pharmaceuticals

See all news